Altimmune (ALT) Cash from Investing Activities (2010 - 2026)

Altimmune (ALT) has reported Cash from Investing Activities for 17 consecutive years, with -$3.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 27.66% year-over-year to -$3.7 million; the TTM figure through Mar 2026 stood at -$131.1 million (down 2272.06% YoY), while the FY2025 annual figure was -$132.5 million, down 366.68% from the prior year.
• Cash from Investing Activities rose to -$3.7 million in Q1 2026 per ALT's latest filing, from -$79.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $101.1 million in Q2 2025 and bottomed at -$149.3 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$13.2 million across 5 years, with a median of -$3.7 million in 2026.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 147900.0% — and 2025, when it sank 12553.79%.
• Altimmune's Cash from Investing Activities stood at $981000.0 in 2022, then plunged by 911.31% to -$8.0 million in 2023, then surged by 271.28% to $13.6 million in 2024, then tumbled by 680.68% to -$79.2 million in 2025, then jumped by 95.34% to -$3.7 million in 2026.
• Business Quant data shows ALT's Cash from Investing Activities at -$3.7 million in Q1 2026, -$79.2 million in Q4 2025, and -$149.3 million in Q3 2025.